Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

December 31, 2010

Study Completion Date

July 31, 2013

Conditions
Multiple Myeloma
Interventions
DRUG

Bort, Dex, and Dox with ALCAR

Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long

Trial Locations (5)

53792

University of Wisconsin Cancer Center, Madison

Unknown

Mercy Health Systems, Janesville

Gundersen Lutheran, La Crosse

Regional Cancer Center, Waukesha/Oconomowoc

Aspirus Wausau Hospital, Aspirus Regional Cancer Center, Wausau

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

University of Wisconsin, Madison

OTHER